OSIVAX

Osivax initiated a phase 2a trial (NCT06582277) to assess OVX836, a broad-spectrum influenza vaccine, as a booster in participants previously vaccinated with OVX836. The study aims to evaluate safety and immunogenicity at Ghent University Hospital's Center for Vaccinology (CEVAC). Topline results are expected by the end of 2025.